(c) if so, whether his Ministry has amended the Drug Policy; and

(d) if so, when and what are the details of amendments?

THE MINISTER OF INDUSTRY (SHIR J. VENGAL RAO): (a) to (d) The details are given in the reply to Starred Question No. 77 for 27th February, 1989.

Price Control on Bulk Drugs

607. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Kelkar Committee has recommended for further liberalisation of price control of drugs and medicines;

(b) if so, what is the total number of bulk drugs recommended for price decontrol by the committee in their supplementary report;

(c) what was the number of Bulk drugs under price control under DPCO, 1979 and what was the number in December, 1988**;**

(d) whether Kelkar Committee recommended for price control of any of price decontrolled drugs as per DPCO, 1987; and

(e) if so, the names of those drugs and how many have been included so far?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a), (b), (d) and (e) The details of major recommendations made by the Kelkar Committee in their Supplementary Report are given in the reply to Starrted Question No. 77 for 27th February, 1989.

(c) While under DPCO, 1979, the number of burk drugs under Price Control was more than 350/ it was 161 drug's under DPCO, 1987, in December, 1988. Out of this all vitamins as bulk drugs, except vitamin A and C, are exempt from price control as required under paragraph 3 of DPCO, 1987. Recently, 15 drugs have been exempted from price control under DPCO, 1987.

Encouragement to Indigenous Technology

608. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Kelkar Committee made recommendations in regard to encouragement of indigenous technology in the country;

(b) whether it is also a fact that the Committee recommended for incentive on such drugs;

(c) what were the number of drugs recommended for exemption from price control on the basis of development of indigenous technology;

(d) whether it is a fact that Kelkar Committee recommended for exemption of certain more drugs in the supplementary report on the same basis; and

(e) if so, what are the names of the drugs?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) The details are given in the reply to Starred Question No. 77 for 27th February, 1989.

Criteria for bringing Price Control Drugs to Price decontrolled category

609. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to state:

(a) whether Government's attention has been drawn to the news item which appeared in the *Economic Times* on the 16th January, 1989 caption 'Kelkar panel for lifting price control on 13 drugs';

(b) if so, what were the criteria on which each of these drugs were recommended for price control in the original report;

(c) what are the basis on which these drugs were recommended for price de control in the supplementary report;

(d) whether the Committee adopted new criteria for deletion of these drugs; and

(e) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO); (a) Yes, Sir.

(b) to (e) The information will be compiled and laid on the Table of the House, as soon as possible.

Price Control on Promethazine

610. DR. BAPU KALDATE: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that his Ministry has excluded Promethazine from price control;

(b) whether it is also a fact that formulation based on this drug has monopoly;

(c) what are the names of formulatovs of this drug and what are the prices of each;

(d) whether it is a fact that the price of the drug and its formulations is very high and decontrol with further increase of price;

(e) whether the major formulators made request for revision of price;

(f) if so, when and whether the request is pending or rejected; and

(g) in which manner the conditions based oi which the request was withheld would no.v be enforced?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) No, **Sir.**

(b) Sales turnover of formulations is not monitored.

(c), (e) and (f) The required details to the extent available will be collected and laid on the Table of the House.

(d) and |g) Do not arise in view of reply to part (a) above.

Government's Reaction on the Kelkar Committee's Supplementary Report

611. DR. RATNAKAR PANDEY: Will the Minister of INDUSTRY be pleased to state:

(a) when was the supplementary report submitted by the Kelkar Committee and what are the details of recommendations;

(b) how many recommendations have been accepted by his Ministry and what are their details: and

(c) by when action on another recommendations will be taken?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (c) The required details are given in the reply to Rajya Sabha Starred Question No. 77 for 27th February, 1989.

Representations for including Drugs Under Price Control

612. DR. (SHRIMATI) SAROJINI MAHISHI: Will the Minister of INDUS TRY be pfeased to state:

(a) The names of drugs for which Kelkar Committee received representations for inclusion under Drugs Price Control Ofder on the basis of non-fulfilment of any exclusion criteria;

(b) how many such representations were received by the Kelkar Committee from consumer organisations and Members of Parliament;

(c) what are the details of basjs given in support of their representations for inclusion of drugs under price control; and

(d> what are the details of their recommendations, and what action has been taken by his Ministry on these recommendations?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (d) Requisite details are given in the reply to Starred Question No. 77. for answer on 27th Februray, 1989.